DNA cancer vaccines: A gene gun approach

Immunology and Cell Biology

Volumn 75, Issue 5, 1997, Pages 456-460

  Mahvi, David M ^a   Sheehy, Michael J ^b   Yang, Ning Sun ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Cancer; DNA; Gene therapy; Vaccines

Indexed keywords

CANCER VACCINE; VIRUS VECTOR;

CANCER IMMUNOTHERAPY; CANCER PREVENTION; EXPRESSION VECTOR; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; HUMAN; REVIEW; VACCINE PRODUCTION;

EID: 0030726020     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1038/icb.1997.70     Document Type: Review

References (34)

1. Roth JA, Cristiano RJ. Gene therapy for cancer: What have we done and where are we going? J. Natl Cancer Inst. 1997; 89: 21-39.
2. Rosenberg SA. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J. Natl Cancer Inst. 1996; 88: 1635-44.
3. Gilboa E. Immunotherapy of cancer with genetically modified tumor vaccines. Semin. Oncol. 1996; 23; 101-7.
4. Yang NS, Sun WH, McCabe D. Developing particle-mediated gene-transfer technology for research into gene therapy of cancer. Mol. Med. Today 1996; 2: 476-81.
5. Dilloo D, Bacon K, Holden W et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat. Med. 1996; 2: 1090-5.
6. Ostrand-Rosenberg S, Clements VK, Thakur A, Cole GA. Transfection of major histocompatibility complex class I and class II genes causes tumor rejection. J. Immunogenet. 1989; 16: 343-9.
7. Armstrong TD, Clements VK, Martin BK, Ting JPY, Ostrand-Rosenberg S. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc. Natl Acad. Sci. USA 1997; 94: 6886-91.
8. Nabel GJ, Nabel EG, Yang ZY et al. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biological activity, and lack of toxicity in humans. Proc. Natl Acad. Sci. USA 1993; 90: 11 307-11.
9. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 1993; 90: 3539-43.
10. Mahvi DM, Burkholder JK, Turner J et al. Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: Implications for a clinically relevant tumor vaccine. Hum. Gene Ther. 1996; 7: 1535-43.
11. Aruga E, Aruga A, Area MJ et al. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12 or GM-CSF. Cancer Gene Ther. 1997; 4: 157-66.
12. Irvine KR, Rao JB, Rosenberg SA, Restifo NP. Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J. Immunol. 1996; 156: 238-45.
13. Zitvogel L, Tahara H, Robbins PD et al. Cancer immunotherapy of established tumors with IL-12: Effective delivery by genetically engineered fibroblasts. J. Immunol. 1995; 155: 1393-403.
14. Tahara H, Lotze MT, Robbins PD, Storkus WJ, Zitvogel L. IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum. Gene Ther. 1995; 6: 1607-24.
15. + T cells by B7-transfected melanoma cells. Science 1993; 259: 368-70.
16. Albertini MA, Emler CA, Schell K, Tans KJ, King DM, Sheehy MJ. Dual expression of human leukocyte antigen molecules and the B7-1 costimulatory molecule (CD80) on human melanoma cells after particle-mediated gene transfer. Cancer Gene Ther. 1996: 3: 192-201.
17. Chen L, Ashe S, Brady WA et al. Co-stimulation of antitumour immunity by the B7 counter-receptor for the T lymphocyte molecule CD28 and CTLA-4. Cell 1992; 71: 1093-102.
18. Zhai Y, Yang JC, Kawakami Y et al. Antigen-specific tumor vaccines: Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. J. Immunol. 1996; 156: 700-10.
19. Conry RM, Widera G, Lobuglio AF et al. Selected strategies to augment polynucleotide immunization. Gene Ther. 1996; 3: 67-74.
20. Yang N-S, Sun WH. Gene gun and other non-viral approaches for cancer gene therapy. Nat. Med. 1995; 1: 481-3.
21. Mule JJ, Yang JC, Lafreniere RL, Shu S, Rosenberg SA. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high dose recombinant interleukin-2. J. Immunol. 1987; 139: 285-94.
22. Borden EC, Sondel PM. Lymphokines and cytokines as cancer treatment: Immunotherapy realized. Cancer 1990; 65: 800-14.
23. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high dose bolus interleukin-2. J. Am. Med. Assoc. 1994; 271: 907-13.
24. Sosman JA, Kohler PC, Hank JA, Moore KH, Bechhofer R, Storer B, Sondel PM. Repetitive weekly cycles of recombinant human interleukin-2: Responses of renal carcinoma with acceptable toxicity. J. Natl Cancer Inst. 1988; 80: 60-3.
25. Thompson JA, Shulman KL, Benyunes MC et al. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma. J. Clin. Oncol. 1993; 10: 960-8.
26. Schiller JH, Hank JA, Storer B et al. A direct comparison of immunological and clinical effects of interleukin-2 with and without interferon-a in humans. Cancer Res. 1993; 53: 1286-92.
27. Hank JA, Albertini M, Wesly OH et al. Clinical and immunologic effects of treatment with murine anti-CD3 monoclonal antibody together with interleukin-2 in patients with cancer. Clin. Cancer Res. 1995; 1: 481-91.
28. Parkinson DR. Lessons from the clinical trials of interleukin-2. Natl Immunol. Cell Growth Regul. 1990; 9: 242-52.
29. Cavallo F, Dipierro F, Giovarelli M et al. Protective and curative potential of vaccination with interleukin-2 gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res. 1993; 53: 5067-70.
30. Schmidt W, Schweighoffer T, Herbst E et al. Cancer vaccines: the interleukin-2 dosage effect. Proc. Natl Acad. Sci. USA 1995; 92: 4711-14.
31. Sun WH, Burkholder JK, Sun J et al. In vivo cytokine gene transfer by gene gun suppresses tumor growth in mice. Proc. Natl Acad. Sci. USA 1995; 92: 2889-93.
32. Berns AJ, Clift S, Cohen LK et al. Phase I study of nonreplicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum. Gene Ther. 1995; 6: 347-68.
33. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell. Biol. 1990; 10: 4239-42.
34. Mahvi DM, Sondel PM, Yang N-S et al. Phase I/IB study of immunization with autologous tumor cells transfected with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma. Hum. Gene Ther. 1997; 8: 875-91.